Back to School: How biopharma can reboot drug development. Access exclusive analysis here

No love letters lost

As the initial sequencing of the human genome enters its last days, it probably was inevitable that the urgency to claim credit and the imperative to make money would collide. Thus the airing of the bickering between the public Human Genome Project Consortium (HGP) and Celera Genomics Corp. has succeeded in putting an all too human tarnish on what is to be proclaimed a noble international achievement.

HGP and CRA (Rockville, Md.), which are racing to sequence the genome, have been in preliminary discussions for a joint effort to merge the two data sets on the sequence, but have been unable to reach a deal on the data merger and the follow-on "finishing efforts" that will take place over the next several years.

In their public venting of frustration, the two sides now also have failed to abide by their agreement to engage in civil discourse.

Last week HGP chose to make public

Read the full 1508 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE